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Abstract
Background: Anxiety disorders are associated with functional disability, sickness absence, and decreased
productivity. Effective treatments of anxiety disorders can result in remission of symptoms. However the effects on
work related outcomes are largely unknown. Exposure in vivo is potentially well fit to improve work-related
outcomes. This study systematically reviews the effectiveness of exposure-in-vivo containing interventions in
reducing work-related adverse outcomes in workers with anxiety disorders.
Methods: A systematic study search was conducted in Medline, Cinahl, Embase and Psycinfo. Two reviewers
independently extracted data and from each study assessed the quality of evidence by using the GRADE approach.
We performed a meta-analysis if data showed sufficient clinical homogeneity.
Results: Seven studies containing 11 exposure-in-vivo interventions were included. Four studies were focused on
Obsessive Compulsive Disorder (OCD), two on Post Traumatic Stress Disorder (PTSD), and one on a mixed group of
OCD and severe phobias. The studies were grouped according to type of anxiety disorder and subsequently according
to type of comparisons. For OCD, exposure-in-vivo containing interventions can yield better work-related outcomes
compared to medication (SSRIs) and relaxation but not better compared to response prevention. The results on anxiety
outcomes were similar. The net contribution of exposure in vivo in two OCD intervention programs is also presented as
a meta-analysis and shows significant positive results on work role limitations. The calculated pooled effect size with
95% confidence interval was 0.72 (0.28, 1.15). For PTSD, exposure-in-vivo containing interventions can yield better work-
related and anxiety-related outcomes compared to a waiting-list but not better compared to imaginal exposure.
Conclusions: Exposure in vivo as part of an anxiety treatment can reduce work-related adverse outcomes in workers
with OCD and PTSD better than various other anxiety treatments or a waiting-list. We recommend that it should be
studied how the results of these studies can be transferred to the practice of occupational health professionals and
how clinicians can make better use of them to improve work-related outcomes. In future research, priority should be
given to high-quality randomised controlled trials (RCTs) in which exposure-in-vivo containing interventions are applied
to a variety of anxiety disorders and compared with other clinical anxiety treatments such as SSRIs. Work-related
outcomes, in particular work functioning and sickness absence, need to be assessed with reliable and valid measures.
Background
Anxiety disorders have a substantial impact on personal
lives, companies, and society and are highly prevalent in
the general population. The twelve-month prevalence
rates among the general adult population in Canada, the
US, and Europe are 12%, 18%, and 12%, respectively
[1-3]. These disorders are associated with functional dis-
abilities in the social, emotional, and physical domains
of life which also affect work [4-6]. Effects on work are
increased unemployment rates, increased sickness
absence, and decreased productivity [6-11]. The annual
costs of anxiety disorders impose a considerable finan-
cial burden on American and European societies, the
bulk of which are due to reduced working capacity or
early retirement [3,12,13]. It is postulated that a
* Correspondence: f.w.noordik@amc.nl
1Coronel Institute of Occupational Health, Academic Medical Center (AMC),
University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The
Netherlands
Full list of author information is available at the end of the article
Noordik et al. BMC Public Health 2010, 10:598
http://www.biomedcentral.com/1471-2458/10/598
© 2010 Noordik et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
substantial part of these costs can be avoided with
greater recognition and appropriate interventions [6].
Cognitive behavioural therapy (CBT), pharmacother-
apy, or a combined treatment of CBT and medication
are effective in symptom reduction for a variety of anxi-
ety disorders [14-23]. Recovery in social functioning,
including work functioning, is an aspect of recovery that
often does not occur completely or takes more time to
manifest than other symptoms, as has been described
for psychiatric symptomatology in general, depressive
symptoms and OCD symptoms [4,14,24-26]. This sug-
gests that more attention paid to return-to-work during
regular treatment or the introduction of specific work-
directed interventions in addition to clinical treatment
might be advantageous.
Exposure in vivo, which is a common behavioural
component of CBT for different anxiety disorders,
might be promising for reducing work-related adverse
outcomes. Exposure in vivo can be aimed directly at
behavioural change in dealing with anxiety-provoking
work situations during return-to-work [27]. Exposure in
vivo provides the opportunity for workers to learn to
deal gradually with anxiety-provoking work situations
during return-to-work or actual work functioning. Other
types of exposure, such as imaginal or interoceptive
exposure, are more indirectly aimed at a real life con-
frontation with anxiety-provoking work situations. Ima-
ginal exposure, for example, is aimed at cognitive
restructuring and can be used in preparation for a real
life confrontation with anxiety-provoking situations.
Furthermore, exposure in vivo is not complicated by the
adverse side effects common in pharmacotherapy, which
can even result in decreased work functioning [28,29].
We considered four dimensions of work functioning for
workers with CMDs relevant as potential effects of expo-
sure in vivo [30]. One dimension describes the economic
aspects related to the output of workers such as in terms
of loss of productivity due to sick leave and associated
costs. A second dimension represents the process of work
functioning by assessing the work role limitations of work-
ers. A third dimension explicates the quality of work e.g.
in terms of errors or a risk of accidents. A fourth dimen-
sion considers the personal effort necessary to remain pro-
ductive such as in terms of extra effort days.
As a recent overview of reducing work-related adverse
effects of exposure in vivo in treatment programmes for
different anxiety disorders is lacking, we aimed to review
these effects systematically. We reviewed studies that
included exposure in vivo as part of a treatment pro-
gramme and compared this approach with either a pro-
gramme without exposure in vivo, a waiting list
condition, placebo treatment, or care as usual. Our
main interest was to determine whether a treatment
programme that included exposure in vivo resulted in
better work-related and anxiety-related outcomes than a
treatment programme without exposure in vivo. More
knowledge of the work-related adverse effects of expo-
sure in vivo in anxiety treatment could support decision
making regarding optimal treatment for workers.
Methods
Search method for identification of studies
A systematic search was conducted in four electronic
databases: MEDLINE (Ovid 1966-2007), CINAHL
(1982-2007), EMBASE (1980-2007), and PsycINFO (Sil-
verplatter 1972-2007). The search was subsequently
extended by checking the references of all retrieved
reviews and the references, citations, and authors of all
included articles.
Four groups of free text words in the title, abstract, or
full text of the article were combined with AND: i.e., we
combined words related to anxiety, exposure, and work
with words referring to controlled or randomised con-
trolled studies.
1. Type of participants (anxiety-related words): fear*
OR fright* OR afraid* OR angst* OR agoraphobia
OR GAD OR OCD OR Phobia OR PTSD OR worr*
OR panic* OR obses* OR intrusive OR irratio* OR
preoccupation OR ruminat* OR compuls* OR catas*
OR escap* OR avoid* OR anx*.
2. Type of intervention (exposure-related words):
vivo* OR reinf* OR habitu* OR exti* OR conditioni*
OR Skinner OR behav* OR stimulus* OR expos*.
3. Type of research design (words related to controlled
and randomised controlled studies): clinical trial OR
Clinical trials OR (clin* adj25 trial*) OR placebos OR
placebo* OR random* OR evaluation studies OR pro-
spective studies OR (control* or prospective* or volun-
teer*) OR ((singl* OR doubl* OR tripl* OR trebl*)
adj25 (blind* OR mask* OR dummy)).
4. Type of outcome (work-related words): job perfor-
mance OR job re-entry OR employment OR (rehabi-
litation, vocational) OR sick leave OR work OR
disability evaluation OR Occupational Therapy OR
return-to-work OR occupational therap* OR occupa-
tional intervention* OR supported employment OR
vocational rehabilitation OR work capacity evalua-
tion OR vocational guidance OR absenteeism OR
occupational health services OR occupational health
OR unemployed OR employed OR unemployment
OR sick* absence OR retirement OR disability pen-
sion OR occupation* OR job OR vocational.
The selected words are partly database-specific (see
Additional file 1: Searchstrings). The work-related words
in section four are mostly selected from a study by
Haafkens et al. on work-related terms in searching for
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literature on chronic diseases (rheumatoid arthritis, dia-
betes mellitus, hearing problems, and depression) [31].
The work-related words: work* and occupation* are sen-
sitive single terms used to locate occupational health
studies as advocated by Verbeek et al. [32]. Furthermore,
to identify studies with the appropriate design, we
selected words related to controlled and randomised
controlled trials from the search strategy of the
Cochrane Collaboration Depression, Anxiety, and Neu-
rosis Group (CCDAN).
Criteria for inclusion/exclusion and procedure
We included studies that met the following five criteria:
1. Participants were selected for the original study
because of their anxiety disorder or anxiety com-
plaints, and were aged between 18 and 65 years.
2. Exposure in vivo was used explicitly as a central
component of therapy, and was performed gradually.
We excluded studies in which the central part of
therapy consisted of only exposure in vitro, imaginal
exposure, or interoceptive exposure.
3. The ‘exposure in vivo’ intervention was compared
with another intervention aimed at diminishing anxi-
ety, such as anxiolytic or antidepressant medication,
cognitive behavioural psychotherapy without expo-
sure, a waiting-list treatment, imaginal or interocep-
tive exposure, a placebo, or care as usual.
4. One or more outcome parameters were related to
work functioning, where work functioning includes
employment status, absenteeism, and presenteeism.
Other than unemployment, relevant work-related
outcomes can be absenteeism measures such as
duration or frequency of sick leave, or measures of
functioning while at the workplace such as the
Work scale of the Social Adjustment Scale (SAS)
and the Sheenan Disability Scale (SDS).
5. The study design was a randomised controlled
trial (RCT) or a clinical controlled trial (CCT). We
also included cluster randomised controlled trials.
Three reviewers (EN, KN, and EK) conducted the
initial selection from the studies identified based on title
and/or abstract. The second selection was performed by
two independent reviewers (EN and EK/KN) who sys-
tematically applied the inclusion and exclusion criteria
to the full-text articles. Disagreements between the two
reviewers were discussed until consensus was reached. If
no consensus could be reached, a third reviewer (KN/
EK) was consulted, and acted as a referee.
Methodological quality
After inclusion, two independent reviewers (EN and KN)
independently estimated the quality of evidence of each
study that was included. To judge the quality of evi-
dence we used the GRADE criteria [33]. In this
approach, the quality of evidence is based on a judge-
ment of the limitations in the design (i.e., risk of bias),
the indirectness of evidence, unexplained heterogeneity
or inconsistency of results, imprecision of results, and
probability of publication bias, respectively. The quality
of evidence can be categorised as high, moderate, low,
and very low. A high quality of evidence is associated
with randomised trials with a low risk of bias. In cases
of unclear or high risk of bias the quality of evidence
was downgraded one level, from high to moderate, if
the study limitations were judged to be serious. In case
of a high risk of bias the quality of evidence was down-
graded two levels, from high to low, if study limitations
were judged very serious. The assessment of the risk of
bias is based on a judgement of the sequence genera-
tion, allocation concealment, blinding of outcome asses-
sors, incomplete outcome data, selective outcome
reporting, and other sources of bias, respectively [33].
Blinding of participants and health care providers were
not used as a criterion, as these aspects are not ade-
quately applicable in RCTs in the field of occupational
health research [34,35]. The risk of bias was finally
judged as high, unclear, or low. Study limitations (i.e.,
risk of bias) was the most relevant criterion to judge the
quality of evidence of the studies in this review. The
other four criteria were hardly applicable to the included
studies.
Data analysis
From the studies with multiple intervention groups, we
selected groups for which exposure in vivo was an
important part of the intervention (intervention groups)
and compared the outcome scores of these groups with
the outcome scores of groups without exposure (control
groups). We considered two types of outcome scores:
work-related and anxiety-related outcomes. A study was
considered to have found positive results when the
treatment programme of the intervention group
improved the outcome score significantly more than the
treatment programme of the control group did (signifi-
cant positive = sp). Studies that found no significant dif-
ferences between the intervention and control groups
reported neutral results (not significant = ns). Studies
which found a significantly worse score for the interven-
tion group compared with the control group were con-
sidered to have produced negative results (significant
negative = sn).
If studies had more than one experimental exposure
group, we considered each experimental group with a
different treatment programme as a separate group. If
studies reported multiple anxiety outcomes for a single
experimental group, we summarised the effects on
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different outcomes by calculating the sum of all positive,
neutral, and negative outcomes.
Whenever significant or non-significant effects were
reported, we calculated the effect size using standardised
mean differences (SMDs), as supported by the available
data. The SMDs were based on the final post-treatment
scores and were calculated with a fixed or random-effect
model [36]. These SMDs are also known as ‘Hedges’
(adjusted) g’. Whenever the statistical significance calcu-
lated differed from that reported by the authors, the cal-
culated SMD was used in the evidence synthesis. For
uniformity of reporting, any improved work-related or
anxiety-related effect that was represented by a negative
value was transformed by multiplying the mean negative
SMD by -1. SMDs of 0.2 or less are considered a small
effect, SMDs of 0.2 or more are considered a medium-
sized effect, and SMDs of more than 0.8 are considered
a large effect [36]. Whenever SMDs and the 95% confi-
dence interval were calculated for multiple comparisons
in one study, we used half of the number of workers
that were reported in the study for the control group
(N/2), in order to prevent a unit-of-analysis error due to
double counting participants [36].
Whenever selected workers, intervention groups,
control groups, and outcomes were considered clini-
cally heterogeneous, we presented the results sepa-
rately. Whenever selected workers, intervention
groups, control groups, and outcomes were considered
sufficiently clinically homogenous, we planned to per-
form a meta-analysis. In addition, in order to study the
net contribution of exposure in vivo, we planned to
perform a meta-analysis of studies in which the only
difference between groups was the application of expo-
sure in vivo, regardless of the content of other compo-
nents of the intervention (e.g., exposure in vivo
included in group CBT plus SSRIs compared to only
SSRIs, as opposed to exposure in vivo at home compared
to response prevention). We calculated a pooled effect size
by pooling SMDs. between groups using a fixed-effect
model. Statistical heterogeneity between experimental
groups was tested with the I2 test. If the calculated I2 score
was lower than 50%, we considered the pooled effect sizes
to be sufficiently statistically homogenous. If I2 was greater
than 50%, we considered the effect sizes to be statistically
heterogeneous and we recalculated the pooled effect size
with a random-effects model [36].
Results
A total of 5,545 publications were retrieved from our
systematic search of four databases. We identified 402
duplications, leaving 5,143 unique studies. Applying the
eligibility inclusion criteria to the title and abstract
eliminated 5,053 studies. Applying the eligibility inclu-
sion criteria to the 90 remaining full-text articles left
only three relevant articles. The extended search
resulted in the selection of another 71 relevant studies,
which were read in full. Another four studies from this
group could be included, resulting in a total of seven
included studies (See Figure 1 for a flowchart of the
inclusion process). The main reason for exclusion of full
text articles was the absence of a specific work-related
outcome.
Characteristics of included studies
Additional file 2 shows the characteristics of the seven
included studies. Four studies had two experimental
groups with different interventions and a common con-
trol group. The other three studies had single experi-
mental and control groups. We present the
characteristics of all experimental groups separately.
Three studies were published before 2000 and four were
published since 2000. Participants in four of the
included studies had an obsessive-compulsive disorder
(OCD) for many years (mean range 9.8-22 years). In one
study, participants had OCD or a severe phobia (mean
duration 8 years). In two studies, participants had post-
traumatic stress disorder (PTSD). The age of the partici-
pants in the studies ranged from 15 to 80 years. Three
studies reported the percentage of participants working
at baseline. Four studies were randomised controlled
trials and three were controlled trials. Follow-up periods
were between 8 and 17 weeks for three studies, 26
weeks for one study, and 12 months for three studies.
The total number of participants in the experimental
and control groups ranged from 6 to 74 and 5 to 75,
respectively. Four studies had been conducted in the
USA, two in the UK, and one in Austria. In two studies,
workers with OCD were treated at a university clinic. In
the other studies, workers with OCD were treated in an
outpatient setting, an out- or inpatient setting, or the
setting was not reported. In one study, workers with
PTSD were treated in an academic or community clinic,
and in the other study workers with PTSD were treated
in an academic clinic.
The treatment programme of the OCD and PTSD
intervention groups consisted mainly of exposure in
vivo. In three intervention groups with OCD, exposure
in vivo was combined with medication therapy (SSRIs
or clomipramine) or response prevention. In one inter-
vention group with PTSD, exposure in vivo was com-
bined with cognitive restructuring. The treatment
programmes for the OCD and PTSD control groups all
consisted of a treatment without exposure in vivo. How-
ever, the content of this treatment varied. Workers with
OCD in control groups received SSRI medication, sys-
tematic self-relaxation, clomipramine medication with
anti-exposure homework, marital therapy, or response
prevention. Workers with PTSD in the control group
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received wait-list or imaginal exposure. Additional file 3
shows a more detailed description of the components,
duration, and provider of the treatment programmes in
the experimental and control condition of each study.
Two studies of OCD and one study of PTSD used the
Work and Social Adjustment Scale as a work-related
outcome measure; the other four studies each used
other work-related outcome measures. Two studies of
OCD used the same anxiety-related outcome measure
(Y-BOC); the other three studies of OCD used multiple
measures for anxiety, obsessions, and compulsive beha-
viour. The two studies of PTSD used various anxiety-
related outcome measures.
Methodological quality
Additional file 4 shows the judgement of the quality of
evidence for the seven included studies and one meta-
analysis. In the risk-of-bias assessment, we found that
one OCD study and one PTSD study had a high risk of
bias and subsequently a low quality of evidence [37,38].
Three OCD studies were found to have an unclear risk
of bias and subsequently a moderate quality of evidence
[39-41]. One OCD and one PTSD study had a low risk
of bias and subsequently a high quality of evidence
[42,43].
Results of data and quality of evidence
Additional file 5 shows the calculated effect sizes on the
work-related outcomes for OCD and PTSD, respectively,
from the studies that were included in the different
comparisons. In Figure 2, we present the calculated
pooled effect size of a meta-analysis of two studies con-
cerning work-related outcomes in workers with OCD.
Additional file 6 shows the calculated effect sizes on the
anxiety-related outcomes for workers with OCD and
PTSD, respectively, from the studies that were included
in the different comparisons. Figure 3 shows a calcu-
lated pooled effect-size of a meta-analysis of two studies
concerning anxiety-related outcomes of OCD. The data
used to calculate the SMDs of the two experimental
groups in Aigner et al. were kindly provided upon our
request [37]. Data from Marks et al. and Cobb et al.
were not requested as these studies were conducted
over twenty years ago [43,40].
Work-related and anxiety-related outcomes for workers
with OCD
Exposure in vivo compared with SSRIs We found sig-
nificant positive work-related effects for exposure in
vivo as part of CBT applied in a group compared with
medication treatment (SSRIs), and for exposure in vivo
applied along with medication (SSRIs) compared with
medication alone (Additional file 5, studies 1a,1b) [37].
The calculated SMDs with 95% confidence intervals
were 1.02 (0.48, 1.55) and 0.73 (0.25, 1.20), respectively.
These effect sizes are considered to be large (>0.8) and
medium-sized (>0.2), respectively. The quality of evi-
dence for these effects was low. We also found a signifi-
cant positive anxiety-related effect of exposure in vivo in
Figure 1 Flowchart of the inclusion and exclusion during the searching process.
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both comparisons (Additional file 6, studies 1a,1b) [37].
The calculated SMDs with 95% confidence intervals
were 0.87 (0.34, 1.39) and 1.00 (0.52, 1.49), respectively,
which are large effect sizes (>0.8). The quality of evi-
dence for these effects was low.
Exposure in vivo compared with self-relaxation We
found a significant positive work-related effect for expo-
sure in vivo as part of CBT applied via a computer com-
pared with systematic self-relaxation and applied by a
clinician compared with systematic self-relaxation
(Additional file 5, studies 2a,2b) [39]. The calculated
SMDs with 95% confidence intervals were 0.35 (0.08,
0.79) and 0.72 (0.28, 1.17), respectively. These effect
sizes are both considered medium-sized (>0.2). The
quality of evidence for these work-related effects was
judged moderate. We also found a significant positive
anxiety-related effect of exposure in vivo in both com-
parisons (Additional file 6, studies 2a,2b) [39]. The cal-
culated SMDs with 95% confidence intervals were 0.72
(0.28, 1.17) and 1.01 (0.55, 1.47), respectively, which are
medium-sized (>0.2) and large effects (>0.8). The quality
of evidence for these anxiety-related effects was
moderate.
Exposure in vivo compared with anti-exposure We
found a significant positive work-related effect of expo-
sure in vivo combined with medication (clomipramine)
compared with medication combined with anti-exposure
work at home (Additional file 5, study 4) [43]. Anti-
exposure means avoiding anxiety or ritual-evoking sti-
muli as much as possible. However, due to a lack of raw
data, a SMD could not be calculated. The quality of evi-
dence for this work-related effect was high. The anxiety-
related effects in the described comparison were also
significantly positive on 9 out of 14 outcome measures
(Additional file 6, study 4) [43]. No significant effect was
reported in the other 5 of 14 measures. We concluded
that overall there was a significant positive anxiety-
related effect. Due to a lack of raw data, SMDs for anxi-
ety-related outcomes were not calculated. The quality of
evidence for this anxiety-related effect was judged high.
Exposure in vivo compared with response prevention
In one study we found a non-significant work-related
effect of exposure in vivo applied at home compared
with response prevention and exposure in vivo applied
at home plus response prevention compared with
response prevention alone (Additional file 5, studies
3a,3b) [41]. The calculated SMDs with 95% confidence
intervals were 0.12 (-1.02, 1.27) and 0.68 (-0.43, 1.79),
respectively. These effect sizes are considered small
(<0.2) and medium-sized (>0.2). The quality of evidence
for these work-related effects was moderate. The anxi-
ety-related effects of exposure in vivo in both compari-
sons were also non-significant (Additional file 6, studies
3a,3b) [41]. The calculated SMDs with 95% confidence
intervals on (self-rated) obsessions were -0.52 (-1.69,
0.64) and -0.03 (-1.10, 1.04), respectively. The calculated
SMDs with 95% confidence intervals on compulsions
were 0.15 (-0.99, 1.30) and 0.21 (-0.86, 1.29), respec-
tively. These effect sizes are considered small (<0.2) and
medium-sized (>0.2). The quality of evidence for these
anxiety-related effects was judged moderate.
Exposure in vivo compared with marital therapy One
study demonstrated a non-significant work-related effect
of exposure in vivo compared with marital therapy for a
mixed group of workers with OCD and severe phobia
(Additional file 5, study 5) [40]. A SMD could not be
Figure 2 Meta-analysis of work-related effect of net contribution of exposure in vivo based on two OCD studies.
Figure 3 Meta-analysis of anxiety-related effect of net contribution of exposure in vivo based on two OCD studies.
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calculated, due to a lack of data. The quality of evidence
for the reported effect was judged moderate. Except for
one positive significant anxiety-related outcome (i.e.,
two main phobic-obsessive target problems), we found
non-significant effects on three other anxiety-related
outcome measures (Additional file 6, study 5) [40]. We
could not calculate a SMD for these outcomes due to a
lack of data. The quality of evidence for the anxiety-
related effects was moderate.
Meta-analysis OCD We could not perform a meta-ana-
lysis on the work-related and anxiety-related data of the
five OCD studies due to clinical heterogeneity, particu-
larly in the control groups (i.e., some received SSRI
medication, others received systematic self-relaxation or
response prevention therapies) [37,39-41,43].
However, we did perform a meta-analysis of the out-
comes of two studies that represents the net contribu-
tion of exposure in vivo. The comparison between
exposure in vivo as part of CBT applied in a group plus
medication (SSRIs) compared with medication (SSRIs)
alone and the comparison between exposure in vivo
applied at home plus response prevention compared
with response prevention only (Additional file 5 and 6,
studies 1b,3b) [37,41] were included in this meta-analy-
sis. Within both comparisons, exposure in vivo was the
only difference between groups. We present the calcu-
lated pooled effect size of the work-related single effect
by means of a meta-analysis in Figure 2. The pooled
SMD with 95% confidence interval was 0.72 (0.28, 1.15),
which favours treatment programmes with exposure in
vivo treatment over treatment programmes without
exposure in vivo. The pooled effect size is considered
medium sized (>0.2). I2 was 0%, indicating no statistical
heterogeneity. The quality of evidence for the pooled
effect was judged moderate.
We present the calculated pooled effect size of the
anxiety-related single effect of exposure in vivo by
means of a meta-analysis in Figure 3. We found a
pooled SMD with 95% confidence interval of 0.54 (-0.16,
1.24), which is a non-significant effect. We used a ran-
dom-effects model, as I2 was greater than 50%. The
quality of evidence for this pooled effect was judged
moderate.
Work-related and anxiety related outcomes for workers
with PTSD
Exposure in vivo compared with waiting list We
found a significant positive work-related effect for pro-
longed exposure in vivo compared with a waiting list
condition and prolonged exposure in vivo plus cognitive
restructuring compared with a waiting list condition
(Additional file 5, studies 6a, 6b) [42]. The calculated
SMDs with 95% confidence intervals were 0.82 (0.12,
1.52) and 0.77 (0.02, 1.51), respectively. These effect
sizes are considered large (>0.8) and medium-sized
(>0.2). The quality of evidence for these effects was
judged high.
Additional file 6 also shows the calculated effect sizes
of exposure in vivo on the PTSD symptoms of workers
with PTSD. The calculated SMDs of three other anxi-
ety-related outcome measures are available on request.
We found a significant positive effect of prolonged
exposure on PTSD symptoms in both comparisons
(Additional file 6, studies 6a, 6b) [42]. The calculated
SMDs with 95% confidence intervals were 1.92 (1.35,
2.49) and 1.80 (1.22, 2.38), respectively, both large effect
sizes (>0.8). The quality of evidence for these anxiety-
related effects was judged high.
Exposure in vivo compared with imaginal exposure
We found a non-significant work-related effect of expo-
sure in vivo compared with imaginal exposure (Addi-
tional file 5, study 7) [38]. The calculated Odds Ratio
with 95% confidence interval was 1.27 (0.49, 3.31). The
quality of evidence for this work-related effect was
judged low. We also found a non-significant anxiety-
related effect of exposure in vivo compared with imagi-
nal exposure (Additional file 6, study 7) [38]. The calcu-
lated SMD with 95% confidence interval was -0.11
(-0.55, 0.33), which is considered a small effect size
(effect size <0.2). The quality of evidence for this anxi-
ety-related effect was judged low.
PTSD meta-analysis We did not perform a meta-
analysis of the two PTSD studies due to heterogeneity
in the control groups (waiting list and imaginal expo-
sure) and included workers (PTSD and PTSD with non-
visual flashbacks). Furthermore, we did not perform a
meta-analysis of the net contribution of exposure in
vivo as we could not find PTSD studies in which expo-
sure in vivo was the only difference between groups.
Discussion
We included seven studies in which workers were trea-
ted with exposure in vivo as the major component of
anxiety treatment. Two studies had a high quality of evi-
dence, three studies had a moderate quality of evidence,
and two studies had a low quality of evidence. Four stu-
dies concerned workers with obsessive-compulsive dis-
orders (OCD), one study concerned a mixed group of
workers with OCD or severe phobias, and two studies
concerned workers with post-traumatic disorder
(PTSD). For OCD we found a low to high quality of evi-
dence that exposure in vivo can reduce adverse work-
related outcomes with a medium to large effect in five
different modalities and comparisons (Group CBT vs.
SSRIs, group CBT plus SSRIs vs. SSRIs, clinician guided
CBT vs. systematic self-relaxation, exposure homework
combined with Clomipramine vs. Clomipramine
with anti-exposure homework). We found moderate evi-
dence that exposure in vivo did not reduce adverse
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work-related outcomes in workers with OCD in three
other modalities and comparisons (computer CBT at
home via telephone vs. systematic self-relaxation, expo-
sure at home vs. response prevention, exposure at home
plus response prevention vs. response prevention).
Moreover, in a meta-analysis of two OCD studies repre-
senting the net contribution of exposure in vivo, we
found moderate evidence of a medium-sized effect on
work-related outcome. Furthermore, we found that this
work-related effect was combined with moderate evi-
dence of no increase in anxiety related outcomes. Based
on both meta-analyses, we may conclude that there is
moderate evidence that anxiety treatments including
exposure in vivo can reduce adverse work-related out-
comes in workers with OCD with a medium-sized
effect, and do not increase anxiety. For workers with
PTSD, we found a high quality of evidence that expo-
sure in vivo can reduce adverse work-related outcomes
with a medium to large effect in two different modalities
and comparisons (prolonged exposure vs. waiting list,
prolonged exposure plus cognitive restructuring vs. wait-
ing list). We found a low quality of evidence that expo-
sure in vivo compared with imaginal exposure did not
differ in improving work-related outcomes. The work-
related effects for workers with PTSD were obtained
without increasing anxiety.
That we found only seven relevant studies for this
review after a comprehensive and sensitive literature
search is a remarkable finding in and of itself. We
included four studies involving workers with OCD, one
study involving a mixed group of workers with OCD
and severe phobias, two studies involving workers with
PTSD, and no studies involving workers with other
anxiety disorders. These findings are in sharp contrast
with the prevalence of studies that have reported an
association between a variety of anxiety disorders and
work-related outcomes such as absence due to sickness,
presenteeism, and decreased productivity. Our findings
in workers with OCD are consistent with the low num-
ber of studies with work-related results in Steketee’s
review focussed on OCD and social functioning, which
is a broader concept and includes work-related, social,
and leisure-related outcomes [14]. Our review had three
studies in common with Steketee’s review.
Another suprising finding is that only one of the seven
included studies investigated an outcome parameter
related to return-to-work, i.e., employment status while
increased sickness absence is frequently reported in
cross-sectional studies [7,10,11,38]. The other studies
investigated self-reported work functioning, which is a
broader concept than return-to-work. In future studies,
return-to-work outcomes should be evaluated more
often.
A third noteworthy finding is that no controlled stu-
dies have been performed in which exposure in vivo was
aimed at specific anxiety-provoking work situations, i.e.,
situations related to specific tasks, social relations, or
workplaces. Avoidance of such tasks, relationships, or
workplaces can hinder good job performance. Specific
work-related anxiety complaints and anxiety disorders
such as work-related panic, work-related phobia, work-
related social phobia, and work-related generalised anxi-
ety exist as clinical phenomena partly independent of
anxiety disorders in general and therefore deserve speci-
fic therapeutic attention [44].
A strength of this review is its sensitive and compre-
hensive search of four electronic databases, using search
words partly based on prior bibliographic research.
Furthermore, we used the GRADE criteria, recom-
mended by the Cochrane Collaboration, to judge the
quality of evidence of included studies.
Although the distinction between high and low-risk of
bias or high and low quality of evidence of studies is
still controversial, it offers the advantage that the pro-
cess of labelling the risk of bias and the quality of evi-
dence is explicit and transparent [45].
Usually, blinding of participants and health care provi-
ders is one of the criteria for assessing risk-of-bias. We
excluded these aspects of the assessment as they lack
applicability in this type of intervention study. Workers
cannot be blinded adequately to the intervention they
receive and health care providers cannot be blinded suf-
ficiently to the intervention they provide [34,35]. Blind-
ing of assessors is the only criterion that remains to
reduce the risk of bias in this type of study.
A weak point of this review is that it is not possible to
evaluate the compliance with exposure in vivo because
this was not reported in the included studies. Thus, we
are uncertain about the minimal dose of exposure in
vivo that could have reduced work-related adverse out-
come. Furthermore, all the included studies evaluated
exposure in vivo in the context of a much broader treat-
ment strategy, rather than by itself. This could have
diminished or strengthened the effect of the treatment,
as interaction may have occurred between the effects of
exposure in vivo and the effects of other components of
the intervention strategy.
A methodological consideration of this review is that
we calculated SMDs based on the final post-treatment
scores, not on the change score. According to the
Cochrane Handbook for Systematic Reviews of Interven-
tions, this is an adequate option [36]. We chose to do so
because final post-treatment scores were available in five
of the seven included studies, so we could compare
SMDs between individual studies. In contrast, the
change score was only available in one study [39].
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Generalising the results of this review to workers with
OCD must be done cautiously, as we found mixed
results in different comparisons between groups. The
results of this review cannot be generalised to anxiety
disorders other than OCD without discussion, as our
included studies mainly concerned workers with OCD
and we found mixed results of exposure in vivo in two
studies that included workers with PTSD.
In future research, priority should be given to high-
quality randomised controlled trials (RCTs) applying
exposure in vivo to a variety of anxiety disorders, and
measuring work-related outcomes as well as anxiety
symptoms. In particular, work-related outcomes such as
work functioning, productivity, and absence due to sick-
ness should be evaluated. Future research should be
aimed at work-related anxiety complaints and disorders,
as they can be distinguished from anxiety disorders in
general. Reliable and valid work-related outcome mea-
sures are needed to evaluate interventions for general
anxiety and for work-related anxiety. Recently developed
measures, such as the MINI work anxiety interview and
the Occupational Functioning Scale, can be considered
for use in such research [46]. Exposure in vivo should
be compared with other effective treatments for anxiety
disorders that are part of usual care such as SSRIs, as
these are more stringent control conditions than waiting
list or relaxation.
Conclusions
Exposure-in-vivo containing interventions can improve
work functioning in workers with OCD and PTSD bet-
ter compared to various other anxiety treatments or a
waiting-list. We recommend that it should be studied
how the results of these studies can be transferred to
the practice of occupational health professionals and
how clinicians can make better use of them to improve
work-related outcomes.
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